HDAC9 and neoplasm: Other examples include genistein, a soy isoflavone, which has been reported in preclinical studies to inhibit DNMT and HDAC activity, reactivate ERα expression in breast cancer cells, and enhance tumor sensitivity to hormonal therapy [37].